We rank companies based on fund manager, research analyst and news sentiment
ALXO stock icon

ALX Oncology
ALXO

$15.6
0.89%
 

About: ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.

Employees: 72

0
Funds holding %
of 6,474 funds
0
Analysts bullish %
of 6 analysts
News positive %

Fund manager confidence

Based on 2023 Q4 SEC filings by fund managers ($100M+ AUM)

327% more capital invested

Capital invested by funds: $160M [Q3] → $681M (+$522M) [Q4]

291% more call options, than puts

Call options by funds: $3.74M | Put options by funds: $956K

200% more funds holding in top 10

Funds holding in top 10: 1 [Q3] → 3 (+2) [Q4]

113% more first-time investments, than exits

New positions opened: 32 | Existing positions closed: 15

106% more repeat investments, than reductions

Existing positions increased: 33 | Existing positions reduced: 16

22% more funds holding

Funds holding: 76 [Q3] → 93 (+17) [Q4]

10.98% more ownership

Funds ownership: 80.88% [Q3] → 91.86% (+10.98%) [Q4]

Research analyst outlook

6 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target
$10
36%
downside
Avg. target
$17.17
10%
upside
High target
$21
35%
upside

6 analyst ratings

positive
83%
neutral
17%
negative
0%
HC Wainwright & Co.
Swayampakula Ramakanth
28%upside
$20
Buy
Reiterated
10 Apr 2024
HC Wainwright & Co.
Swayampakula Ramakanth
28%upside
$20
Buy
Maintained
11 Mar 2024
Piper Sandler
Christopher Raymond
35%upside
$21
Overweight
Maintained
8 Mar 2024
Stifel
Bradley Canino
10%downside
$14
Hold
Downgraded
8 Mar 2024
Jefferies
Michael Yee
15%upside
$18
Buy
Upgraded
8 Dec 2023

Financial journalist opinion